Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
2023-10-23 14:25:26 ET More on Seattle Genetics Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Seagen ticks higher as EU approves $43B sale to Pfizer Pfizer likely turned over all documents to FTC for Seagen acquistion - r...
2023-10-13 09:38:00 ET More on Astellas Pharma ADR Astellas: Earnings Power, Asset Factors Attractive, Reiterate Hold On Valuation Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript Merck succeeds in Phase 3 trial for bladder cancer therapy Apellis...
2023-10-05 07:30:43 ET More on Merck Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck: A Blue-Chip Dividend Stock Worth Buying US government to stop distributing Merck's CO...
2023-09-27 08:59:28 ET Summary Poseida Therapeutics exhibits robust financials with Q2 2023 collaboration revenue surging to $20.01M and a recent $50M Astellas investment extending its cash runway. Despite stock underperformance, Poseida's diversified CAR-T pipeline shows momentum...
2023-09-22 06:49:12 ET More on Merck Seeking Alpha’s Quant Rating on Merck Historical earnings data for Merck Financial information for Merck Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck: A Blue-Chip Dividend St...
2023-09-19 09:29:45 ET More on Astellas, Apellis, etc. Sticking With Apellis: Navigating Syfovre's Safety Measures In A Volatile Market Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade) Wells Fargo ups Apellis to overweight, stock climbs ...
2023-09-14 04:51:56 ET Astellas Pharma ( OTCPK:ALPMY ) intends to build a new facility, at an approximate cost of €330M in Tralee, Co. Kerry. Ireland. This investment will expand capacity and capabilities for aseptic drug products, reinforce stable production...
2023-09-07 15:39:56 ET Japanese drugmaker Astellas ( OTCPK:ALPMF ) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly instituted policy was unconstitutional. Astellas was one of...
2023-08-23 08:12:30 ET More on Pfizer Pfizer Stock: The Right Time To Buy Now (Technical Analysis) Pfizer: Doubling Down Buying Opportunity Is Here Pfizer's Unexpected Strength: Bullish Case Emerges Amid New Covid-19 Wave Pfizer Inc. ( PFE ) Q2 2023 Ear...
2023-08-16 12:41:31 ET Summary Astellas has closed its Iveric bio, Inc. deal in July and reported JPY 375Bn in quarterly sales in Q1. The company's earnings power and asset factors are bullish, but valuation factors are keeping me neutral. From this, I am closely watching the ...
News, Short Squeeze, Breakout and More Instantly...
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...